Literature DB >> 1000085

Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and disease in various animal plasmas.

H Saito, G Goldsmith, R Waldmann.   

Abstract

Fitzgerald factor (high molecular weight kininogen) is an agent in normal human plasma that corrects the impaired in vitro surface-mediated plasma reactions of blood coagulation, fibrinolysis, and kinin generation observed in Fitzgerald trait plasma. To assess the possible pathophysiologic role of Fitzgerald factor, its titer was measured by a functional clot-promoting assay. Mean +/- SD in 42 normal adults was 0.99+/-0.25 units/ml, one unit being the activity in 1 ml of normal pooled plasma. No difference in titer was noted between normal men and women, during pregnancy, or after physical exercise. Fitzgerald factor activity was significantly reduced in the plasmas of eight patients with advanced hepatic cirrhosis (0.40+/-0.09 units/ml) and of ten patients with disseminated intravascular coagulation (0.60+/-0.30 units/ml), but was normal in plasmas of patients with other congenital clotting factor deficiencies, nephrotic syndrome, rheumatoid arthritis, systemic lupus erythematosus, or sarcoidosis, or under treatment with warfarin. The plasmas of 21 mammalian species tested appeared to contain Fitzgerald factor activity, but those of two avian, two repitilian, and one amphibian species did not correct the coagulant defect in Fitzgerald trait plasmas.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1000085

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments.

Authors:  G H Goldsmith; H Saito; O S Ratnoff
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

Review 2.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

3.  Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.

Authors:  C Cordova; F Violi; C Alessandri; D Ferro; M Saliola; F Balsano
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

4.  Plasma kallikrein activation and inhibition during typhoid fever.

Authors:  R W Colman; R Edelman; C F Scott; R H Gilman
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

5.  Kallikrein-kinin system in chronic subdural haematomas: its roles in vascular permeability and regulation of fibrinolysis and coagulation.

Authors:  H Fujisawa; H Ito; S Kashiwagi; S Nomura; M Toyosawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-10       Impact factor: 10.154

6.  Proteomics Analysis to Identify and Characterize the Biomarkers and Physical Activities of Non-Frail and Frail Older Adults.

Authors:  Ching-Hung Lin; Chen-Chung Liao; Chi-Huang Huang; Yu-Tang Tung; Huan-Cheng Chang; Mei-Chich Hsu; Chi-Chang Huang
Journal:  Int J Med Sci       Date:  2017-02-23       Impact factor: 3.738

7.  Relation between structure and correcting activity of bovine high molecular weight kininogen upon the clotting time of Fitzgerald-trait plasma.

Authors:  A G Scicli; R Waldmann; J A Guimaraes; G Scicli; O A Carretero; H Kato; Y N Han; S Iwanaga
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.